<p>BioLife Solutions（纳斯达克代码：BLFS - 获取免费报告）于周四发布了其财报。该医疗设备供应商报告本季度每股收益为 0.04 美元，超出市场共识预期的（0.03 美元）0.07 美元，Zacks 报道。BioLife Solutions 的净利润率为负的 38.98%，股本回报率为负的 6.61%。BioLife Solutions 更新了其 2025 财年的每股收益指引。</p>
<p>获取 <strong>BioLife Solutions</strong> 的提醒：</p>
<h2>BioLife Solutions 股票上涨 3.9%</h2>
<ul>
<li>现在值得投资的最佳生物科技股票</li>
</ul>
<p>周五午盘交易中，BLFS 的股价上涨 0.88 美元，达到 23.24 美元。该公司的交易量为 1,161,730 股，而其平均交易量为 385,880 股。BioLife Solutions 的 1 年最低价为 17.70 美元，1 年最高价为 29.55 美元。该公司的市值为 11 亿美元，市盈率为-21.92，贝塔值为 2.01。该公司的债务与股本比率为 0.03，速动比率为 1.78，流动比率为 2.78。该公司的 50 日简单移动平均线为 23.84 美元，200 日简单移动平均线为 25.27 美元。</p>
<h2>分析师设定新目标价</h2>
<p>几家研究公司最近对 BLFS 发布了报告。HC Wainwright 将 BioLife Solutions 的目标价从 27.00 美元上调至 30.00 美元，并在 3 月 6 日的研究报告中给予该股票 “买入” 评级。StockNews.com 在 4 月 24 日的研究报告中将 BioLife Solutions 的评级从 “持有” 下调至 “卖出”。一位股票研究分析师给予该股票 “卖出” 评级，六位分析师给予该股票 “买入” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 31.17 美元。</p>
<ul>
<li>3 只小型医疗股今日市场波动</li>
</ul>
<p><strong>查看我们对 BioLife Solutions 的最新股票分析</strong></p>
<h2>内部人士买卖情况</h2>
<p>在其他新闻中，执行副总裁 Aby J. Mathew 于 4 月 1 日（星期二）出售了 10,589 股公司股票。该股票以平均价格 22.66 美元出售，总交易额为 239,946.74 美元。交易完成后，该执行副总裁现在直接持有 309,576 股公司股票，价值约为 7,014,992.16 美元。这代表其持股减少了 3.31%。该交易在向 SEC 的法律文件中披露，可以通过此链接访问。此外，首席财务官 Troy Wichterman 于 4 月 1 日（星期二）出售了 25,687 股股票。该股票以平均价格 22.66 美元出售，总价值为 582,067.42 美元。交易完成后，首席财务官现在持有 189,242 股公司股票，价值约为 4,288,223.72 美元。该交易使其持股减少了 11.95%。该销售的披露信息可以在这里找到。在过去的九十天里，内部人士已出售 72,127 股公司股票，价值 1,676,533 美元。公司内部人士持有公司股票的 2.20%。</p>
<h2>BioLife Solutions 公司简介</h2>
<p>（获取免费报告）</p>
<p>BioLife Solutions, Inc.在美国、欧洲、中东、非洲及国际市场开发、制造和销售细胞和基因治疗（CGT）行业的生物生产工具和服务。该公司的产品用于生物基疗法的基础和应用研究以及商业生产。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 BioLife Solutions</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>GlobalFoundries 股票触底：反弹即将来临？</li>
<li>何时出售股票以获利或亏损</li>
<li>高盛看好 MercadoLibre 股票的原因</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>分析师最青睐的比特币矿工 CleanSpark：值得关注吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 BioLife Solutions 吗？</h2>
<p>在你考虑 BioLife Solutions 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 BioLife Solutions 并不在名单上。</p>
<p>虽然 BioLife Solutions 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BLFS

<p>BioLife Solutions（纳斯达克代码：BLFS）报告的季度每股收益为 0.04 美元，超出预期的-0.03 美元，超出幅度为 0.07 美元。尽管净利润率为-38.98%，股本回报率为-6.61%，但股价仍上涨 3.9%，达到 23.24 美元。分析师设定的共识目标价为 31.17 美元，HC Wainwright 将其目标价从 27.00 美元上调至 30.00 美元。内部人士减持股票的情况被注意到，管理层减少了持股。BioLife Solutions 专注于细胞和基因治疗行业的生物生产工具</p>

<p>BioLife Solutions (NASDAQ:BLFS - Get Free Report) posted its earnings results on Thursday. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07, Zacks reports. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. BioLife Solutions updated its FY 2025 guidance to EPS.</p>
<div class="lb-trans"><p>BioLife Solutions（纳斯达克代码：BLFS - 获取免费报告）于周四发布了其财报。该医疗设备供应商报告本季度每股收益为 0.04 美元，超出市场共识预期的（0.03 美元）0.07 美元，Zacks 报道。BioLife Solutions 的净利润率为负的 38.98%，股本回报率为负的 6.61%。BioLife Solutions 更新了其 2025 财年的每股收益指引。</p>
</div><p>Get <strong>BioLife Solutions</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>BioLife Solutions</strong> 的提醒：</p>
</div><h2>BioLife Solutions Stock Up 3.9 %</h2>
<div class="lb-trans"><h2>BioLife Solutions 股票上涨 3.9%</h2>
</div><ul>
<li>Best Biotech Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在值得投资的最佳生物科技股票</li>
</ul>
</div><p>Shares of BLFS traded up $0.88 during midday trading on Friday, hitting $23.24. The company had a trading volume of 1,161,730 shares, compared to its average volume of 385,880. BioLife Solutions has a 1 year low of $17.70 and a 1 year high of $29.55. The firm has a market capitalization of $1.10 billion, a P/E ratio of -21.92 and a beta of 2.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company's 50-day simple moving average is $23.84 and its 200-day simple moving average is $25.27.</p>
<div class="lb-trans"><p>周五午盘交易中，BLFS 的股价上涨 0.88 美元，达到 23.24 美元。该公司的交易量为 1,161,730 股，而其平均交易量为 385,880 股。BioLife Solutions 的 1 年最低价为 17.70 美元，1 年最高价为 29.55 美元。该公司的市值为 11 亿美元，市盈率为-21.92，贝塔值为 2.01。该公司的债务与股本比率为 0.03，速动比率为 1.78，流动比率为 2.78。该公司的 50 日简单移动平均线为 23.84 美元，200 日简单移动平均线为 25.27 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research firms recently issued reports on BLFS. HC Wainwright increased their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 6th. StockNews.com lowered shares of BioLife Solutions from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $31.17.</p>
<div class="lb-trans"><p>几家研究公司最近对 BLFS 发布了报告。HC Wainwright 将 BioLife Solutions 的目标价从 27.00 美元上调至 30.00 美元，并在 3 月 6 日的研究报告中给予该股票 “买入” 评级。StockNews.com 在 4 月 24 日的研究报告中将 BioLife Solutions 的评级从 “持有” 下调至 “卖出”。一位股票研究分析师给予该股票 “卖出” 评级，六位分析师给予该股票 “买入” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 31.17 美元。</p>
</div><ul>
<li>3 Small-Cap Medical Stocks Moving Markets Today</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小型医疗股今日市场波动</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on BioLife Solutions</strong></p>
<div class="lb-trans"><p><strong>查看我们对 BioLife Solutions 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In other news, EVP Aby J. Mathew sold 10,589 shares of the company's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $239,946.74. Following the completion of the transaction, the executive vice president now directly owns 309,576 shares of the company's stock, valued at approximately $7,014,992.16. This represents a 3.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Troy Wichterman sold 25,687 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $582,067.42. Following the completion of the transaction, the chief financial officer now owns 189,242 shares in the company, valued at approximately $4,288,223.72. The trade was a 11.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,127 shares of company stock worth $1,676,533. Company insiders own 2.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Aby J. Mathew 于 4 月 1 日（星期二）出售了 10,589 股公司股票。该股票以平均价格 22.66 美元出售，总交易额为 239,946.74 美元。交易完成后，该执行副总裁现在直接持有 309,576 股公司股票，价值约为 7,014,992.16 美元。这代表其持股减少了 3.31%。该交易在向 SEC 的法律文件中披露，可以通过此链接访问。此外，首席财务官 Troy Wichterman 于 4 月 1 日（星期二）出售了 25,687 股股票。该股票以平均价格 22.66 美元出售，总价值为 582,067.42 美元。交易完成后，首席财务官现在持有 189,242 股公司股票，价值约为 4,288,223.72 美元。该交易使其持股减少了 11.95%。该销售的披露信息可以在这里找到。在过去的九十天里，内部人士已出售 72,127 股公司股票，价值 1,676,533 美元。公司内部人士持有公司股票的 2.20%。</p>
</div><h2>BioLife Solutions Company Profile</h2>
<div class="lb-trans"><h2>BioLife Solutions 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc.在美国、欧洲、中东、非洲及国际市场开发、制造和销售细胞和基因治疗（CGT）行业的生物生产工具和服务。该公司的产品用于生物基疗法的基础和应用研究以及商业生产。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than BioLife Solutions</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 BioLife Solutions</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>GlobalFoundries 股票触底：反弹即将来临？</li>
<li>何时出售股票以获利或亏损</li>
<li>高盛看好 MercadoLibre 股票的原因</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>分析师最青睐的比特币矿工 CleanSpark：值得关注吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=BLFS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioLife Solutions Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BioLife Solutions 吗？</h2>
</div><p>Before you consider BioLife Solutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 BioLife Solutions 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 BioLife Solutions 并不在名单上。</p>
</div><p>While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioLife Solutions 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

BioLife Solutions (NASDAQ:BLFS) 公布了财报结果，每股收益比预期高出 0.07 美元